Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ471MR)

This product GTTS-WQ471MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ471MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ14433MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ11254MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ7113MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ2530MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ13488MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ185MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ14398MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW